Syndax Pharmaceuticals
(NASDAQ) SNDX
Syndax Pharmaceuticals Financials at a Glance
Market Cap
$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$217.17M
Net Income (TTM)
-$243.25M
EPS (TTM)
-$2.80
P/E Ratio
-7.81
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$22.10
Volume
61,976
Open
$21.82
Price
$22.10
Volume
61,976
Open
$21.82
Previous Close
$22.10
Daily Range
$21.25 - $22.19
52-Week Range
$8.59 - $25.59
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$22.10
Volume
61,976
Open
$21.82
Previous Close
$22.10
Daily Range
$21.25 - $22.19
52-Week Range
$8.59 - $25.59
Estimated Earnings Date
Aug 3, 2026
SNDX News
SNDX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Syndax Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
298
CEO
Michael A. Metzger, MBA
Website
www.syndax.comHeadquarters
New York City, MA 02451, US
SNDX Financials
Key Financial Metrics (TTM)
Gross Margin
97.96%
Operating Margin
-102.93%
Net Income Margin
-112.01%
Return on Equity
-256.66%
Return on Capital
-66.43%
Return on Assets
-51.46%
Earnings Yield
-12.80%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
88.61M
Volume
61.98K
Avg. Volume
1.84M
Financials (TTM)
Gross Profit
$212.73M
Operating Income
-$223.53M
EBITDA
-$162.50M
Operating Cash Flow
-$278.16M
Capital Expenditure
-$187.00K
Free Cash Flow
-$278.35M
Cash & ST Invst.
$352.06M
Total Debt
$345.36M
Syndax Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$64.86M
+223.6%
Gross Profit
$62.23M
+224.8%
Gross Margin
95.94%
N/A
Market Cap
$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$7.16M
N/A
Employees
270
N/A
Net Income
-$42.67M
+49.7%
EBITDA
-$30.82M
+63.2%
Quarterly Fundamentals
Total Cash
$352.06M
-31.8%
Total Debt
$345.36M
+18700.2%
Accounts Receivable
$60.69M
+182.5%
Inventory
$34.95M
+649.3%
Long Term Debt
$344.87M
+23635.2%
Short Term Debt
$488.00K
+27.1%
Return on Assets
-51.46%
N/A
Return on Invested Capital
-57.84%
N/A
Free Cash Flow
-$50.35M
+47.1%
Operating Cash Flow
-$50.35M
+47.1%